Literature DB >> 6538196

Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator.

C Zamarron, H R Lijnen, D Collen.   

Abstract

The kinetics of the activation of plasminogen by tissue-type plasminogen activator were studied in the presence and the absence of CNBr-digested fibrinogen as a soluble cofactor. Michaelis-Menten kinetics applied and the kinetic parameters obtained were very similar to those previously reported for the activation in the presence of solid phase fibrin (Hoylaerts, M., Rijken, D. C., Lijnen, H. R., and Collen, D. (1982) J. Biol. Chem. 257, 2912-2919). The affinity of the enzyme for plasminogen dramatically increases in the presence of the soluble cofactor while the catalytic rate constant does not change significantly (KM drops from 83 to 0.18 microM and kcat increases from 0.07 to 0.28 s-1 for tissue-type plasminogen activator of melanoma origin). Fragments containing the lysine-binding sites of plasminogen compete with plasminogen for interaction with CNBr-digested fibrinogen. The dissociation constant of this interaction was found to be 4.5 microM for the high affinity lysine-binding site. No difference was found in the kinetic parameters for the activation of plasminogen by either tissue-type plasminogen activator of melanoma origin or by glycosylated forms of tissue-type plasminogen activator obtained by recombinant DNA technology. The present findings obtained in a homogenous liquid milieu support the previously proposed mechanism of the activation of plasminogen by tissue-type plasminogen activator in the presence of fibrin. This mechanism involves binding of both tissue-type plasminogen activator and plasminogen to fibrin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538196

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Authors:  P Golino; J T Willerson
Journal:  Tex Heart Inst J       Date:  1991

Review 2.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

3.  Kinetic studies on the effect of heparin and fibrin on plasminogen activators.

Authors:  R Fears
Journal:  Biochem J       Date:  1988-01-01       Impact factor: 3.857

Review 4.  Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.

Authors:  R Fears
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

5.  The effect of heparin and fibrin on the enzymatic efficiencies of thrombolytics in vitro.

Authors:  R Fears
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.

Authors:  R Cassels; R Fears; R A Smith
Journal:  Biochem J       Date:  1987-10-15       Impact factor: 3.857

Review 7.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

8.  Kinetic studies on novel plasminogen activators. Demonstration of fibrin enhancement for hybrid enzymes comprising the A-chain of plasmin (Lys-78) and B-chain of tissue-type plasminogen activator (Ile-276) or urokinase (Ile-159).

Authors:  R Fears; I Dodd; H Ferres; J H Robinson
Journal:  Biochem J       Date:  1990-03-15       Impact factor: 3.857

9.  Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali O Azghani; Sophia Karandashova; Chris Schaefer; Serge V Yarovoi; Paul J Declerck; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

10.  Longistatin, a plasminogen activator, is key to the availability of blood-meals for ixodid ticks.

Authors:  M Khyrul Islam; M Abdul Alim; Takeharu Miyoshi; Takeshi Hatta; Kayoko Yamaji; Yasunobu Matsumoto; Kozo Fujisaki; Naotoshi Tsuji
Journal:  PLoS Pathog       Date:  2011-03-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.